The Latest Breaking News on Pharma

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market.

The application for children ages 6 months to under 6 years is expected to be completed later this year.

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should drive its growth in the coming quarters. Given GILD’s discounted valuation, we think it could be wise to buy this…

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

‘These video challenges, which often target youths, can harm people — and even cause death,’ the agency said

More than 4 million Americans have rolled up their sleeves for the new omicron-specific booster shots

The United States is significantly cutting back the number of Pfizer/BioNTech COVID-19 vaccine doses it will buy for donation to poorer nations this year, Pfizer said on Thursday, citing diminished demand for the shots in those countries.

WASHINGTON — President Joe Biden’s administration has slashed its target for COVID-19 vaccine donations abroad this year, amending a contract with Pfizer Inc. in the latest sign that world demand for the shots has collapsed.

WASHINGTON — Senate committee leaders have struck an agreement to reauthorize five-year user fee deals for the Food and Drug Administration, although details of a broader stopgap government spending bill remain unfinished.